6) Arimoto A, Kitagawa K, Mita N, et al. Effect of rebamipide ophthalmic suspension on signs and symptoms of keratoconjunctivitis sicca in Sjögren syndrome patients with or without punctal occlusions. Cornea 2014;33:806-11.
7) Kinoshita S, Awamura S, Oshiden K, et al. Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study. Ophthalmology 2012;119:2471-8.
9) Jin-Sil P, Sun-Hee H, SeungCheon Y, et al. Immune modulation by rebamipide in a mouse model of Sjogren's syndrome via T and B cell regulation. Immunol Lett 2019;214:1-7.
13) Kinoshita S, Oshiden K, Awamura S, et al. A randomized, multicenter phase 3 study comparing 2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the treatment of dry eye. Ophthalmology 2013;120:1158-65.
14) Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome: a consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis 2017;76:9-16.
17) Asiedu K, Kyei S, Mensah SN, et al. Ocular Surface Disease Index (OSDI) versus the Standard Patient Evaluation of Eye Dryness (SPEED): a study of a nonclinical sample. Cornea 2016;35:175-80.
18) Moon JY, Yoon HJ, Yoon KC. Efficacy of intense pulsed light treatment in patients with Sjögren’s syndrome associated with meibomian gland dysfunction. J Korean Ophthalmol Soc 2021;62:1581-91.
19) Chun YS, Park IK. Reliability of 4 clinical grading systems for corneal staining. Am J Ophthalmol 2014;157:1097-102.
22) Arita R, Itoh K, Inoue K, Amano S. Noncontact infrared meibography to document age-related changes of the meibomian glands in a normal population. Ophthalmology 2008;115:911-5.
24) Hong S, Kim T, Chung SH, et al. Recurrence after topical non-preserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren's syndrome. J Ocul Pharmacol Ther 2007;23:78-82.
26) Vehof J, Utheim TP, Bootsma H, Hammond CJ. Advances, limitations and future perspectives in the diagnosis and management of dry eye in Sjögren's syndrome. Clin Exp Rheumatol 2020;38 Suppl 126:301-9.
27) Perry HD, Doshi-Carnevale S, Donnenfeld ED, et al. Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction. Cornea 2006;25:171-5.
29) Kim CE, Kim YJ, Hwang MW, et al. Cevimeline-induced anti-inflammatory effect through upregulations of mucins in the ocular surface of a dry eye mouse model. Biomed Pharmacother 2021;139:111571.
30) Kinoshita S, Awamura S, Nakamichi N, et al. A multicenter, open-label, 52-week study of 2% rebamipide (OPC-12759) ophthalmic suspension in patients with dry eye. Am J Ophthalmol 2014;157:576-83.e1.
34) Foulks GN, Forstot SL, Donshik PC, et al. Clinical guidelines for management of dry eye associated with Sjögren disease. Ocul Surf 2015;13:118-32.